or Try an Advanced Search...

    Technical Analysis for BYSI - BeyondSpring, Inc.

    Grade Last Price % Change Price Change
    D 2.17 -4.41% -0.10
    BYSI closed down 6.58 percent on Thursday, April 25, 2024, on 11 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Up
    Historical BYSI trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish -4.41%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.41%
    Inside Day Range Contraction -4.41%
    Wide Bands Range Expansion -4.41%
    20 DMA Resistance Bearish -10.70%
    Crossed Above 50 DMA Bullish -10.70%
    New Uptrend Bullish -10.70%
    Wide Bands Range Expansion -10.70%
    Up 3 Days in a Row Strength -10.70%
    Up 4 Days in a Row Strength -10.70%
    Older End-of-Day Signals for BYSI ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 1 hour ago
    Down 3% about 1 hour ago
    Down 2 % about 1 hour ago
    60 Minute Opening Range Breakdown about 3 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    BYSI Chart by TradingView
    Basic chart:

    Profile

    BeyondSpring, Inc. Description

    BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia

    Is BYSI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 25 BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
    Mar 6 Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
    Feb 26 BeyondSpring regains Nasdaq compliance as price surges above $1
    Feb 26 BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
    Jan 11 BeyondSpring gets Nasdaq delinquency notice
    Jan 10 BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
    Dec 18 BeyondSpring receives Nasdaq notice regarding minimum bid price requirements
    Nov 7 BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibi...
    Oct 31 BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
    Oct 30 BeyondSpring regains compliance with Nasdaq minimum bid price rule
    See more BYSI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.0
    52 Week Low 0.6534
    Average Volume 260,497
    200-Day Moving Average 1.30
    50-Day Moving Average 2.36
    20-Day Moving Average 2.43
    10-Day Moving Average 2.03
    Average True Range 0.28
    RSI (14) 47.92
    ADX 28.23
    +DI 24.97
    -DI 22.56
    Chandelier Exit (Long, 3 ATRs) 2.91
    Chandelier Exit (Short, 3 ATRs) 2.60
    Upper Bollinger Bands 3.56
    Lower Bollinger Band 1.30
    Percent B (%b) 0.43
    BandWidth 93.33
    MACD Line -0.13
    MACD Signal Line -0.12
    MACD Histogram -0.0101
    Fundamentals Value
    Market Cap 88.57 Million
    Num Shares 39 Million
    EPS -0.71
    Price-to-Earnings (P/E) Ratio -3.20
    Price-to-Sales 35.99
    Price-to-Book 5.38
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.49
    Resistance 3 (R3) 2.51 2.46 2.45
    Resistance 2 (R2) 2.46 2.40 2.45 2.44
    Resistance 1 (R1) 2.37 2.37 2.34 2.34 2.43
    Pivot Point 2.31 2.31 2.30 2.30 2.31
    Support 1 (S1) 2.22 2.26 2.19 2.20 2.11
    Support 2 (S2) 2.16 2.22 2.15 2.10
    Support 3 (S3) 2.07 2.16 2.09
    Support 4 (S4) 2.05